ENCORE-MEDIA-GROUP
20.4.2016 16:24:45 CEST | Business Wire | Press release
The IoT Tech Expo , Europe’s leading Internet of Things conference and exhibition welcomes Samsung , Vodafone and Ubuntu on board as platinum sponsors for their upcoming event in Berlin , Germany on the 13-14th June. The two day event will cover a range of industries including manufacturing, healthcare, logistics, transport, government, energy and automotive.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160420005975/en/
Over the 2 days there will be 5 dedicated conference tracks :
Topics include: connected car, smart home, customer experience, smart energy, connected home and monetisation
Speakers from: Tado, Shazam, Deutsche Telekom, Dixons Carphone, Ford, Honda and Jaguar Land Rover
Topics include: smart logistics, M2M, fleet management, digitalisation, smart manufacturing, predictive maintenance and telematics
Speakers from: DHL, Sandvik, Volvo, Konecranes, GE, Statoil, Postnord and TVH
Topics include: smart transportation, urban travel, carbon neutral, smart grids, sustainable cities, energy and big data
Speakers from: Continental, E.ON, City of Nice, City of Copenhagen, Bristol Is Open and GE
Topics include: data analytics, mass data collection, privacy challenges, big data modelling, and cyber security
Speakers from: Lufthansa Systems, European Parliament, Swiss Re, Orange and Konecranes
Topics include: robotics, development, connectivity, standards, investment, start-ups, wearables, AR, VR, future fashion, funding and healthcare
Speakers from: Husqvarna Group, Ubuntu, ETH Zurich, IDA Ireland, W3C, TUV, Samsung and Startupbootcamp
View the full speaker line-up, conference agendas and register your pass here: www.iottechexpo.com/germany
Super early bird prices end Friday 29th April so register now to save up to €295 on your delegate pass!
To learn more about the IoT Tech Expo and register your pass, visit the corresponding sites:
• IoT Tech Expo Central Europe : 13-14th June, Berlin Congress Center bcc, Germany
• IoT Tech Expo North America : 20-21st October, Santa Clara Convention Center, San Francisco, CA
• IoT Tech Expo Global : 23-24th January 2017, Olympia, London
For speaking, sponsorship and exhibitor enquiries please contact the team at enquiries@iottechexpo.com or call on +44 (0) 117 980 9023.
NOTES FOR EDITORS
About IoT Tech Expo
The IoT Tech Expo World Series (www.iottechexpo.com ) hosts top level content and discussion, introducing and exploring the latest innovations in the Internet of Things arena. It brings together key industries including Manufacturing, Transport, Health, Logistics, Government, Energy and Automotive.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160420005975/en/
Contact:
IoT Tech Expo
Sarah Wheeler
Events Marketing & Conference
Executive
sarah@iottechexpo.com
+44
(0) 117 980 9023
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom